Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 70 articles:
HTML format



Single Articles


    December 2022
  1. DWYER-NIELD LD, McArthur DG, Hudish TM, Hudish LI, et al
    PPARgamma agonism inhibits progression of premalignant lesions in a murine lung squamous cell carcinoma model.
    Int J Cancer. 2022;151:2195-2205.
    PubMed     Abstract available


  2. YU F, Peng M, Bai J, Zhu X, et al
    Comprehensive characterization of genomic and radiologic features reveals distinct driver patterns of RTK/RAS pathway in ground-glass opacity pulmonary nodules.
    Int J Cancer. 2022;151:2020-2030.
    PubMed     Abstract available


    November 2022
  3. YU Y, Chen K, Fan Y
    Extensive-Stage Small-Cell Lung Cancer: Current Management and Future Directions.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34346.
    PubMed     Abstract available


  4. NISHIYAMA H, Funamizu T, Iwata H, Endo H, et al
    Low apolipoprotein A1 was associated with increased risk of cancer mortality in patients following percutaneous coronary intervention: A 10-year follow-up study.
    Int J Cancer. 2022;151:1482-1490.
    PubMed     Abstract available


  5. YANG LH, Lee RK, Kuo MH, Miao CC, et al
    Neuronal survival factor VGF promotes chemoresistance and predicts poor prognosis in lung cancers with neuroendocrine feature.
    Int J Cancer. 2022;151:1611-1625.
    PubMed     Abstract available


    October 2022
  6. WU WY, Haider Z, Feng X, Heath AK, et al
    Assessment of the EarlyCDT-Lung test as an early biomarker of lung cancer in ever-smokers - A retrospective nested case-control study in two prospective cohorts.
    Int J Cancer. 2022 Oct 28. doi: 10.1002/ijc.34340.
    PubMed     Abstract available


  7. WEI Y, Xu B, He Q, Chen P, et al
    Serum total folate, 5-methyltetrahydrofolate and vitamin B12 concentrations on incident risk of lung cancer.
    Int J Cancer. 2022 Oct 2. doi: 10.1002/ijc.34307.
    PubMed     Abstract available


    September 2022
  8. BEHRENS T, Ge C, Vermeulen R, Kendzia B, et al
    Occupational exposure to nickel and hexavalent chromium and the risk of lung cancer in a pooled analysis of case-control studies (SYNERGY).
    Int J Cancer. 2022 Sep 2. doi: 10.1002/ijc.34272.
    PubMed     Abstract available


  9. YANG Z, Tian H, Li L, Li C, et al
    PSC subtyping based on TTF-1 and p40 expression reveals distinct molecular characteristics and therapeutic strategies.
    Int J Cancer. 2022;151:717-729.
    PubMed     Abstract available


  10. YUI Y, Kumai J, Watanabe K, Wakamatsu T, et al
    Lung fibrosis is a novel therapeutic target to suppress lung metastasis of osteosarcoma.
    Int J Cancer. 2022;151:739-751.
    PubMed     Abstract available


    August 2022
  11. RAJAN A, Gray JE, Devarakonda S, Birhiray R, et al
    Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-Squamous Non-Small Cell Lung Cancer.
    Int J Cancer. 2022 Aug 27. doi: 10.1002/ijc.34267.
    PubMed     Abstract available


  12. AKHOUNDOVA D, Hussung S, Sivakumar S, Topfer A, et al
    ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.
    Int J Cancer. 2022 Aug 22. doi: 10.1002/ijc.34257.
    PubMed     Abstract available


  13. MUI CW, Chan WN, Chen B, Cheung AH, et al
    Targeting YAP1/TAZ in non-small-cell lung carcinoma: from molecular mechanisms to precision medicine.
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34249.
    PubMed     Abstract available


  14. GAO G, Cui L, Zhou F, Jiang T, et al
    Special issue "The advance of solid tumor research in China": FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer.
    Int J Cancer. 2022 Aug 16. doi: 10.1002/ijc.34239.
    PubMed     Abstract available


  15. RASHIDIAN H, Hadji M, Gholipour M, Naghibzadeh-Tahami A, et al
    Opium use and risk of lung cancer: A multicenter case-control study in Iran.
    Int J Cancer. 2022 Aug 13. doi: 10.1002/ijc.34244.
    PubMed     Abstract available


  16. MARTINI G, Ciardiello D, Dallio M, Famiglietti V, et al
    Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.
    Int J Cancer. 2022;151:473-480.
    PubMed     Abstract available


  17. BUERGY D, Wurschmidt F, Gkika E, Horner-Rieber J, et al
    Stereotactic body radiotherapy of adrenal metastases-A dose-finding study.
    Int J Cancer. 2022;151:412-421.
    PubMed     Abstract available


    July 2022
  18. HEATH AK, Muller DC, van den Brandt PA, Critselis E, et al
    Diet-wide association study of 92 foods and nutrients and lung cancer risk in the European Prospective Investigation into Cancer and Nutrition study and the Netherlands Cohort Study.
    Int J Cancer. 2022 Jul 13. doi: 10.1002/ijc.34211.
    PubMed     Abstract available


  19. KORHONEN T, Hjelmborg J, Harris JR, Clemmensen S, et al
    Cancer in twin pairs discordant for smoking: The Nordic Twin Study of Cancer.
    Int J Cancer. 2022;151:33-43.
    PubMed     Abstract available


    June 2022
  20. YARMOLINSKY J, Amos CI, Hung RJ, Moreno V, et al
    Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk.
    Int J Cancer. 2022 Jun 23. doi: 10.1002/ijc.34180.
    PubMed     Abstract available


  21. BISCHOFF P, Trinks A, Wiederspahn J, Obermayer B, et al
    The single-cell transcriptional landscape of lung carcinoid tumors.
    Int J Cancer. 2022;150:2058-2071.
    PubMed     Abstract available


  22. ZAORSKY NG, Wang X, Lehrer EJ, Tchelebi LT, et al
    Retrospective comparative effectiveness research: Will changing the analytical methods change the results?
    Int J Cancer. 2022;150:1933-1940.
    PubMed     Abstract available


  23. MOONEN L, Mangiante L, Leunissen DJG, Lap LMV, et al
    Differential Orthopedia Homeobox expression in pulmonary carcinoids is associated with changes in DNA methylation.
    Int J Cancer. 2022;150:1987-1997.
    PubMed     Abstract available


  24. LI M, Zhang L, Charvat H, Callister ME, et al
    The influence of postscreening follow-up time and participant characteristics on estimates of overdiagnosis from lung cancer screening trials.
    Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34167.
    PubMed     Abstract available


  25. MAILLE E, Levallet J, Dubois F, Antoine M, et al
    A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial.
    Int J Cancer. 2022;150:1889-1904.
    PubMed     Abstract available


    May 2022
  26. WONG KY, Cheung AH, Chen B, Chan WN, et al
    Cancer-associated fibroblasts in non-small cell lung cancer: from molecular mechanisms to clinical implications.
    Int J Cancer. 2022 May 23. doi: 10.1002/ijc.34127.
    PubMed     Abstract available


  27. SU C, Zhou J, Qiang H, Zhao J, et al
    Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced non-small-cell lung cancer patients with ALK fusion in China.
    Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34123.
    PubMed     Abstract available


    April 2022
  28. GUO LW, Meng QC, Zheng LY, Chen Q, et al
    Special issue "The advance of solid tumor research in China": Participants with a family history of cancer have a higher participation rate in low-dose computed tomography for lung cancer screening.
    Int J Cancer. 2022 Apr 1. doi: 10.1002/ijc.34010.
    PubMed     Abstract available


    March 2022
  29. ZHAO Y, Gao YT, Zhang X, Rockwood AL, et al
    Endogenous sex hormones, aromatase activity and lung cancer risk in postmenopausal never-smoking women.
    Int J Cancer. 2022 Mar 26. doi: 10.1002/ijc.34005.
    PubMed     Abstract available


  30. ABRAHAM G, Noronha V, Rajappa S, Agarwal A, et al
    The clinical utility and safety of short-course immune checkpoint inhibitors in multiple tumours-A real-world multicentric study from India.
    Int J Cancer. 2022;150:1045-1052.
    PubMed     Abstract available


  31. HERMANS BCM, Derks JL, Hillen LM, van der Baan I, et al
    In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma.
    Int J Cancer. 2022;150:802-815.
    PubMed     Abstract available


    February 2022
  32. NGUYEN PT, Katanoda K, Saito E, Hori M, et al
    Trends in lung cancer incidence by gender, histological type and stage at diagnosis in Japan, 1993-2015: A multiple imputation approach.
    Int J Cancer. 2022 Feb 9. doi: 10.1002/ijc.33962.
    PubMed     Abstract available


    December 2021
  33. ZHAO Y, Li S, Yang X, Chu L, et al
    Overall survival benefit of Osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant non-small cell lung cancer with brain metastasis.
    Int J Cancer. 2021 Dec 16. doi: 10.1002/ijc.33904.
    PubMed     Abstract available


  34. BAEK YH, Kang EJ, Hong S, Park SH, et al
    Survival outcomes of patients with non-small cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors.
    Int J Cancer. 2021 Dec 7. doi: 10.1002/ijc.33892.
    PubMed     Abstract available


    October 2021
  35. BOOSMAN RJ, Dorlo TPC, de Rouw N, Burgers JA, et al
    Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment.
    Int J Cancer. 2021;149:1576-1584.
    PubMed     Abstract available


  36. MIURA A, Yamada D, Nakamura M, Tomida S, et al
    Oncogenic potential of human pluripotent stem cell-derived lung organoids with HER2 overexpression.
    Int J Cancer. 2021;149:1593-1604.
    PubMed     Abstract available


    September 2021
  37. HUANG Y, Soon YY, Aminkeng F, Tay SH, et al
    Risk factors for Immune-related Adverse Events from anti-PD-1 or anti PD-L1 treatment in an Asian cohort of non-small cell lung cancer patients.
    Int J Cancer. 2021 Sep 25. doi: 10.1002/ijc.33822.
    PubMed     Abstract available


  38. HUANG CH, Ju JS, Chiu TH, Huang AC, et al
    Afatinib treatment in a large real-world cohort of non-small cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation.
    Int J Cancer. 2021 Sep 24. doi: 10.1002/ijc.33821.
    PubMed     Abstract available


  39. ROGAVA M, Braun AD, van der Sluis TC, Shridhar N, et al
    Tumor cell intrinsic TLR4 signaling promotes melanoma progression and metastatic dissemination.
    Int J Cancer. 2021 Sep 16. doi: 10.1002/ijc.33804.
    PubMed     Abstract available


    August 2021
  40. JI M, Du L, Ma Z, Xie J, et al
    Circulating C-reactive protein increases lung cancer risk: results from a prospective cohort of UK Biobank.
    Int J Cancer. 2021 Aug 27. doi: 10.1002/ijc.33780.
    PubMed     Abstract available


  41. LIU L, Erickson NT, Ricard I, von Weikersthal LF, et al
    Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized phase III trial FIRE-3 (AIO KRK-0306).
    Int J Cancer. 2021 Aug 25. doi: 10.1002/ijc.33775.
    PubMed     Abstract available


  42. RISSANEN E, Heikkinen S, Seppa K, Ryynanen H, et al
    Incidence trends and risk factors of lung cancer in never smokers - Pooled analyses of seven cohorts.
    Int J Cancer. 2021 Aug 16. doi: 10.1002/ijc.33765.
    PubMed     Abstract available


  43. TANIGUCHI H, Natori Y, Miyagi Y, Hayashi K, et al
    Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14-specific chimeric siRNA/nanocarrier complex.
    Int J Cancer. 2021;149:646-656.
    PubMed     Abstract available


    July 2021
  44. ROSIGKEIT S, Kruchem M, Thies D, Kreft A, et al
    Definitive evidence for Club cells as progenitors for mutant Kras/Trp53-deficient lung cancer.
    Int J Cancer. 2021 Jul 31. doi: 10.1002/ijc.33756.
    PubMed     Abstract available


  45. BUERGY D, Wurschmidt F, Gkika E, Horner-Rieber J, et al
    Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis.
    Int J Cancer. 2021;149:358-370.
    PubMed     Abstract available


    June 2021
  46. DOMINE GOMEZ M, Csoszi T, Jaal J, Kudaba I, et al
    Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
    Int J Cancer. 2021 Jun 10. doi: 10.1002/ijc.33705.
    PubMed     Abstract available


    May 2021
  47. MU R, Liu H, Luo S, Patz EF Jr, et al
    Genetic variants of CHEK1, PRIM2 and CDK6 in the mitotic phase-related pathway are associated with nonsmall cell lung cancer survival.
    Int J Cancer. 2021 May 31. doi: 10.1002/ijc.33702.
    PubMed     Abstract available


  48. YU X, Sheng J, Pan G, Fan Y, et al
    Real-World Utilization of EGFR TKIs and Prognostic Factors for Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases.
    Int J Cancer. 2021 May 10. doi: 10.1002/ijc.33677.
    PubMed     Abstract available


  49. XIA Y, Ying S, Jin R, Wu H, et al
    Application of a classifier combining bronchial transcriptomics and chest CT features facilitates the diagnostic evaluation of lung cancer in smokers and non-smokers.
    Int J Cancer. 2021 May 8. doi: 10.1002/ijc.33675.
    PubMed     Abstract available


  50. HAMFJORD J, Guren TK, Glimelius B, Sorbye H, et al
    Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS- or BRAF-mutated metastatic colorectal cancer.
    Int J Cancer. 2021 May 7. doi: 10.1002/ijc.33672.
    PubMed     Abstract available


  51. MORGAN E, Arnold M, Rutherford M, Bardot A, et al
    The impact of reclassifying cancers of unspecified histology on international differences in survival for small cell and non-small cell lung cancer (ICBP SurvMark-2 project).
    Int J Cancer. 2021 May 1. doi: 10.1002/ijc.33620.
    PubMed     Abstract available


    April 2021
  52. HENNESSY M, Wahba A, Felix K, Cabrera M, et al
    Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma.
    Int J Cancer. 2021;148:1928-1937.
    PubMed     Abstract available


  53. CAI L, Chen Y, Tong X, Wu X, et al
    The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients.
    Int J Cancer. 2021 Apr 2. doi: 10.1002/ijc.33583.
    PubMed     Abstract available


  54. HUANG RSP, Haberberger J, Sokol E, Schrock AB, et al
    Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.
    Int J Cancer. 2021;148:1778-1788.
    PubMed     Abstract available


  55. SHI Z, Wei J, Na R, Resurreccion WK, et al
    Cystic fibrosis F508del carriers and cancer risk: Results from the UK Biobank.
    Int J Cancer. 2021;148:1658-1664.
    PubMed     Abstract available


    March 2021
  56. LAUTZ TB, Farooqui Z, Jenkins T, Heaton TE, et al
    Thoracoscopy vs thoracotomy for the management of metastatic osteosarcoma: A Pediatric Surgical Oncology Research Collaborative Study.
    Int J Cancer. 2021;148:1164-1171.
    PubMed     Abstract available


    February 2021
  57. HEIDRICH I, Ackar L, Mossahebi Mohammadi P, Pantel K, et al
    Liquid biopsies: Potential and challenges.
    Int J Cancer. 2021;148:528-545.
    PubMed     Abstract available


    January 2021
  58. LILJEDAHL H, Karlsson A, Oskarsdottir GN, Salomonsson A, et al
    A gene expression-based single sample predictor of lung adenocarcinoma molecular subtype and prognosis.
    Int J Cancer. 2021;148:238-251.
    PubMed     Abstract available


    November 2020
  59. MCGUIRE JJ, Nerlakanti N, Lo CH, Tauro M, et al
    Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.
    Int J Cancer. 2020;147:2811-2823.
    PubMed     Abstract available


  60. HAAKENSEN VD, Khadse A, Sandhu V, Halvorsen AR, et al
    Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy.
    Int J Cancer. 2020;147:2957-2966.
    PubMed     Abstract available


  61. MA J, Klemm J, Gerardo-Ramirez M, Frappart L, et al
    Cluster of differentiation 44 promotes osteosarcoma progression in mice lacking the tumor suppressor Merlin.
    Int J Cancer. 2020;147:2564-2577.
    PubMed     Abstract available


  62. CHENG C, Zhao Y, Schaafsma E, Weng YL, et al
    An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
    Int J Cancer. 2020;147:2621-2633.
    PubMed     Abstract available


    October 2020
  63. THURMAIER J, Heinemann V, Engel J, Schubert-Fritschle G, et al
    Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival.
    Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33364.
    PubMed     Abstract available


    September 2020
  64. SIRRI E, Kieschke J, Vohmann C, Katalinic A, et al
    Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: A population-based study.
    Int J Cancer. 2020;147:1548-1558.
    PubMed     Abstract available


  65. ENGLINGER B, Laemmerer A, Moser P, Kallus S, et al
    Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib.
    Int J Cancer. 2020;147:1680-1693.
    PubMed     Abstract available


    August 2020
  66. GRAU N, Scherer SD, Rothley M, Rosswag S, et al
    Spatiotemporally controlled induction of gene expression in vivo allows tracking the fate of tumor cells that traffic through the lymphatics.
    Int J Cancer. 2020;147:1190-1198.
    PubMed     Abstract available


  67. MENGONI M, Braun AD, Gaffal E, Tuting T, et al
    The aryl hydrocarbon receptor promotes inflammation-induced dedifferentiation and systemic metastatic spread of melanoma cells.
    Int J Cancer. 2020 Aug 13. doi: 10.1002/ijc.33252.
    PubMed     Abstract available


    May 2020
  68. ZONNEVILLE J, Colligan S, Grant S, Miller A, et al
    Blockade of p38 kinase impedes the mobilization of protumorigenic myeloid populations to impact breast cancer metastasis.
    Int J Cancer. 2020 May 25. doi: 10.1002/ijc.33050.
    PubMed     Abstract available


  69. HE Q, Li X, He L, Li Y, et al
    Pericyte dysfunction due to Shb gene deficiency increases B16F10 melanoma lung metastasis.
    Int J Cancer. 2020 May 22. doi: 10.1002/ijc.33110.
    PubMed     Abstract available


    March 2020
  70. KATO M, Onoyama I, Yoshida S, Cui L, et al
    Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
    Int J Cancer. 2020 Mar 11. doi: 10.1002/ijc.32965.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: